FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1857665725> ?p ?o ?g. }

• W1857665725 endingPage "678" @default.
• W1857665725 startingPage "671" @default.
• W1857665725 abstract "PURPOSE To determine whether granulocyte colony-stimulating factor (G-CSF) administered before, during, and after fludarabine plus cytarabine (ara-C; FA) chemotherapy affected complete response (CR) rate, infection rate, blood count recovery, or survival in patients with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). PATIENTS AND METHODS A total of 112 patients with newly diagnosed AML (n = 69) or MDS (n = 43) received G-CSF 400 micrograms/m2/d 1 day before (presenting WBC count < 50,000/microL) and/or during (all patients) fludarabine 30 mg/m2/d and ara-C 2 g/m2/d for 5 days (FLAG). G-CSF continued until a CR was achieved. Results were compared with those in 85 newly diagnosed patients (54 AML, 31 MDS) previously treated with FA without G-CSF. RESULTS Patients in both groups were relatively old (median age of all patients, 63 years), and were likely to have prognostically unfavorable cytogenetic abnormalities (36% had abnormalities of chromosomes 5 and 7 [-5/-7]). G-CSF accelerated recovery to > or = 1,000 neutrophils (P < .0001; median, 34 days for FA, 21 days for FLAG), but logistic regression provided no evidence that the CR rate was higher with FLAG than with FA (P = .50), with unadjusted CR rates of 63% and 53%, respectively. This may reflect relatively high rates of death before neutrophil recovery in both groups. Rates of infection were similar in both groups. The follow-up duration in remission is short, and much of these data remain censored. To date, survival is similar with FA and FLAG. CONCLUSION On average, G-CSF before, during, and after FA had no effect on CR or infection rates in this population, in which elderly patients and poor prognostic factors were prevalent. The use of FA and laminar airflow rooms rather than more usual therapy needs to be considered when analyzing the results." @default.
• W1857665725 created "2016-06-24" @default.
• W1857665725 creator A5002347804 @default.
• W1857665725 creator A5004888325 @default.
• W1857665725 creator A5006104041 @default.
• W1857665725 creator A5014102823 @default.
• W1857665725 creator A5016607292 @default.
• W1857665725 creator A5028026524 @default.
• W1857665725 creator A5038399226 @default.
• W1857665725 creator A5048669186 @default.
• W1857665725 creator A5057920623 @default.
• W1857665725 creator A5090435894 @default.
• W1857665725 date "1994-04-01" @default.
• W1857665725 modified "2023-10-17" @default.
• W1857665725 title "Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor." @default.
• W1857665725 cites W1545612590 @default.
• W1857665725 cites W1556614514 @default.
• W1857665725 cites W1602123006 @default.
• W1857665725 cites W1819781110 @default.
• W1857665725 cites W1969474912 @default.
• W1857665725 cites W1979300931 @default.
• W1857665725 cites W1991918209 @default.
• W1857665725 cites W2020214980 @default.
• W1857665725 cites W2024081693 @default.
• W1857665725 cites W2063384143 @default.
• W1857665725 cites W2074490646 @default.
• W1857665725 cites W2083948119 @default.
• W1857665725 cites W2103163020 @default.
• W1857665725 cites W2135729119 @default.
• W1857665725 cites W2187668060 @default.
• W1857665725 cites W2266624725 @default.
• W1857665725 cites W2404252714 @default.
• W1857665725 cites W2431965920 @default.
• W1857665725 cites W2438080541 @default.
• W1857665725 cites W2440618123 @default.
• W1857665725 cites W1983392832 @default.
• W1857665725 cites W2995133996 @default.
• W1857665725 doi "https://doi.org/10.1200/jco.1994.12.4.671" @default.
• W1857665725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7512125" @default.
• W1857665725 hasPublicationYear "1994" @default.
• W1857665725 type Work @default.
• W1857665725 sameAs 1857665725 @default.
• W1857665725 citedByCount "284" @default.
• W1857665725 countsByYear W18576657252012 @default.
• W1857665725 countsByYear W18576657252013 @default.
• W1857665725 countsByYear W18576657252014 @default.
• W1857665725 countsByYear W18576657252015 @default.
• W1857665725 countsByYear W18576657252016 @default.
• W1857665725 countsByYear W18576657252017 @default.
• W1857665725 countsByYear W18576657252018 @default.
• W1857665725 countsByYear W18576657252019 @default.
• W1857665725 countsByYear W18576657252020 @default.
• W1857665725 countsByYear W18576657252021 @default.
• W1857665725 countsByYear W18576657252023 @default.
• W1857665725 crossrefType "journal-article" @default.
• W1857665725 hasAuthorship W1857665725A5002347804 @default.
• W1857665725 hasAuthorship W1857665725A5004888325 @default.
• W1857665725 hasAuthorship W1857665725A5006104041 @default.
• W1857665725 hasAuthorship W1857665725A5014102823 @default.
• W1857665725 hasAuthorship W1857665725A5016607292 @default.
• W1857665725 hasAuthorship W1857665725A5028026524 @default.
• W1857665725 hasAuthorship W1857665725A5038399226 @default.
• W1857665725 hasAuthorship W1857665725A5048669186 @default.
• W1857665725 hasAuthorship W1857665725A5057920623 @default.
• W1857665725 hasAuthorship W1857665725A5090435894 @default.
• W1857665725 hasConcept C126322002 @default.
• W1857665725 hasConcept C136119220 @default.
• W1857665725 hasConcept C141071460 @default.
• W1857665725 hasConcept C202444582 @default.
• W1857665725 hasConcept C203014093 @default.
• W1857665725 hasConcept C2776694085 @default.
• W1857665725 hasConcept C2776730729 @default.
• W1857665725 hasConcept C2776755627 @default.
• W1857665725 hasConcept C2777767877 @default.
• W1857665725 hasConcept C2778041864 @default.
• W1857665725 hasConcept C2778461978 @default.
• W1857665725 hasConcept C2779263901 @default.
• W1857665725 hasConcept C2780007613 @default.
• W1857665725 hasConcept C2780817109 @default.
• W1857665725 hasConcept C33923547 @default.
• W1857665725 hasConcept C71924100 @default.
• W1857665725 hasConcept C90924648 @default.
• W1857665725 hasConceptScore W1857665725C126322002 @default.
• W1857665725 hasConceptScore W1857665725C136119220 @default.
• W1857665725 hasConceptScore W1857665725C141071460 @default.
• W1857665725 hasConceptScore W1857665725C202444582 @default.
• W1857665725 hasConceptScore W1857665725C203014093 @default.
• W1857665725 hasConceptScore W1857665725C2776694085 @default.
• W1857665725 hasConceptScore W1857665725C2776730729 @default.
• W1857665725 hasConceptScore W1857665725C2776755627 @default.
• W1857665725 hasConceptScore W1857665725C2777767877 @default.
• W1857665725 hasConceptScore W1857665725C2778041864 @default.
• W1857665725 hasConceptScore W1857665725C2778461978 @default.
• W1857665725 hasConceptScore W1857665725C2779263901 @default.
• W1857665725 hasConceptScore W1857665725C2780007613 @default.
• W1857665725 hasConceptScore W1857665725C2780817109 @default.
• W1857665725 hasConceptScore W1857665725C33923547 @default.
• W1857665725 hasConceptScore W1857665725C71924100 @default.

• next